We have come a long way in the past few years in treating metastatic melanoma,” announced John A. Thompson, MD, Medical Director of the Phase I Clinical Trials Program, Co-Director of the Melanoma Clinic, Seattle Cancer Care Alliance, and Professor in the Medical Oncology Division, University of Washington School of Medicine. “We are now talking of response rates in the 60% range, which was almost unheard of a few years ago,” he continued. Dr. Thompson also serves as Vice-Chair of the NCCN Guidelines Panel for Melanoma.
Hodi FS, O'Day SJ, McDermott DF. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–723.
Robert C, Thomas L, Bondarenko I. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517–2526.
Schadendorf D, Hodi FS, Robert C. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015;33:1889–1894.
Topalian SL, Sznol M, McDermott DF. Survival durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020–1030.
Larkin J, Chiarion-Sileni V, Gonzalez R. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23–34.
Eggermont AM, Chiarion-Sileni V, Grob JJ. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015;16:522–530.
Andtbacka RH, Kaufman HL, Collichio F. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015;33:2780–2788.
Long GV, Stroyakovskiy D, Gogoas H. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015;386:444–451.
Long GV, Weber JS, Infante JR. Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol 2016;34:871–878.
Larkin JMG, Yan Y, McArthur GA. Update of progression-free survival and correlative biomarker analysis from coBRIM: phase III study of cobimetinib plus vemurafenib in advanced BRAF-mutated melanoma [abstract]. J Clin Oncol 2015;33(Suppl):Abstract 9006.